Eagle Pharmaceuticals, Inc. (EGRX) Financial Statements
Eagle Pharmaceuticals, Inc. (EGRX) files with the U.S. Securities and Exchange Commission under CIK 0000827871. 10KGenie shows its annual and quarterly statements from SEC filings.
Key Figures, Fiscal Year 2022
- Revenue
- $316.61 million
- Net Income
- $35.64 million
- Total Assets
- $406.16 million
- Net Cash from Operations
- $50.70 million
Fiscal year ended Dec 31, 2022. Latest periodic SEC filing: Aug 9, 2023. Source: SEC filings (EDGAR XBRL).
Open the full financial statements for EGRX in 10KGenie
Data from SEC EDGAR filings. 10KGenie is not affiliated with the SEC. SEC Filing History